Quanterix Corporation (QTRX)

Quanterix Corp.'s stock price has been influenced by several events over the past six months. As of January 2, 2026, the stock price was $6.43 per share, a 45.83% decline from January 6, 2025. On January 9, 2026, the stock experienced a significant gain of 23.81%, rising to $8.06. The 52-week trading range for QTRX has been between $4.05 and $10.90. In the third quarter of 2025, Quanterix reported revenue of $40.2 million, a 12% year-over-year increase, but its EPS missed expectations. The company announced targeted annual cost reductions of approximately $30 million in May 2025, aiming for positive cash flow by 2026. In November 2025, Quanterix announced Board and Leadership Changes, followed by the appointment of Everett Cunningham as President and CEO, effective January 19, 2026. Kent Lake PR LLC publicly criticized the company on June 11, 2025, for not scheduling its 2025 Annual Meeting.

Analysis of Quanterix Corp. data suggests some seasonal tendencies, with a "Buy Date" of October 23 and a "Sell Date" of February 15 showing a geometric average return of 19.69% above the S&P 500 Total Return Index over the past six years. This seasonal timeframe correlates poorly with the broader Healthcare sector's period of seasonal strength.

Quanterix Corporation is a life sciences company focused on developing and marketing ultra-sensitive digital immunoassay platforms to advance precision health. The company operates in the Healthcare sector, including Life Sciences Tools and Services, Medical Specialties, Advanced Medical Equipment & Technology, and Medical Devices industries. Its major products and services are based on its Simoa technology, which enables the detection of protein biomarkers at very low concentrations. Key offerings include instruments like the HD-X, SR-X, and SP-X, assays and consumables such as Simoa Assay Kits and NfL ELISA kits, and services like contract research through its Accelerator Laboratory. The company's technology and products are primarily utilized in research for neurology, oncology, immunology, inflammation, cardiology, and infectious diseases.

Quanterix Corporation's operations and market reach extend across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company is headquartered in Billerica, Massachusetts, United States.

Quanterix's brand reputation has been positively impacted by scientific advancements and studies, including a landmark study published in Nature that redefined the prevalence of Alzheimer's Disease neuropathology and another study demonstrating a dual GFAP/NfL blood test approach for personalized Multiple Sclerosis monitoring. However, the company faced scrutiny due to criticism from Kent Lake PR LLC regarding the delay of the 2025 Annual Meeting.

Quanterix Corp. has significant institutional ownership, ranging from 74.31% to 76.52% of its shares, while individual investors hold approximately 6.6% of the shares. Major institutional owners include Portolan Capital Management, LLC, Ameriprise Financial Inc, BlackRock, Inc., Vanguard Group Inc, and Kent Lake Pr Llc. Insider sentiment has been positive, with high-impact open-market purchases totaling $5.79 million over the last year.